Previous 10 | Next 10 |
Gainers: Altus Midstream (ALTM) +150%.Hall of Fame Resort & Entertainment (HOFV) +118%.Oncternal Therapeutics (ONCT) +82%.Upwork (UPWK) +41%.Aptevo Therapeutics (APVO) +40%.Resideo Technologies (REZI) +35%.Aurora Cannabis (ACB) +34%.Kaixin Auto (KXIN) +33%.Falcon Minerals (...
Bluebird bio (BLUE) slumps 15% premarket on light volume in apparent response to its announcement after the close yesterday related to the planned U.S. marketing application for its LentiGlobin gene therapy for sickle cell disease ((SCD)).It generally agrees with the FDA that the cl...
bluebird bio (BLUE) -15% on Q3 earnings release.Hanesbrands (HBI) -14% on Q3 earnings release.Ping Identity Holding (PING) -13% on Q3 earnings release.Aptevo Therapeutics (APVO) -12% after providing updates on preliminary data in its ongoing APVO436 Phase 1 ...
Updated results from ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin™ for sickle cell disease gene therapy (bb1111) Long-term efficacy and safety results for betibeglogene autotemcel gene therapy in adult and pediatric patients with beta-thalassemia across genoty...
Gainers: [[ALTM]] +54.6%. [[UPWK]] +24.6%. [[QCOM]] +13.2%. [[APHA]] +10.1%. [[MTW]] +9.5%.Losers: [[BLUE]] -13.9%. [[ELF]] -9.4%. [[INGN]] -8.9%. [[AXNX]] -8.7%. [[PING]] -8.7%. For further details see: ALTM, UPWK, AXNX and INGN among after-hours movers
bluebird bio (BLUE): Q3 GAAP EPS of -$2.94 beats by $0.08.Revenue of $19.27M (+116.3% Y/Y) misses by $6.2M.Shares -12.47% AH.Press Release For further details see: bluebird bio EPS beats by $0.08, misses on revenue
– Company to host conference call today, November 4, 2020 at 4:30PM ET - bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2020 and shared recent operational progress. “While...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
The following slide deck was published by bluebird bio, Inc. in conjunction with this event. For further details see: Bluebird Bio (BLUE) Investor Presentation - Slideshow
CRISPR Therapeutics is a gene-editing company founded in 2013 focused on the development and application of CRISPR/Cas9 for therapeutics. CRSP's pipeline consists of 9 therapeutics: 4 early-clinical phases targeting TDT, SCD, and immuno-oncology and 5 in the research phase. CRSP e...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...